Colestipol
Niacin
Resins, Plant
Flammable, amorphous, vegetable products of secretion or disintegration, usually formed in special cavities of plants. They are generally insoluble in water and soluble in alcohol, carbon tetrachloride, ether, or volatile oils. They are fusible and have a conchoidal fracture. They are the oxidation or polymerization products of the terpenes, and are mixtures of aromatic acids and esters. Most are soft and sticky, but harden after exposure to cold. (From Grant & Hackh's Chemical Dictionary, 5th ed & Dorland, 28th ed)
Lovastatin
A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.
Hyperlipoproteinemia Type II
Hypolipidemic Agents
Blinking
Mortuary Practice
Commerce
The interchange of goods or commodities, especially on a large scale, between different countries or between populations within the same country. It includes trade (the buying, selling, or exchanging of commodities, whether wholesale or retail) and business (the purchase and sale of goods to make a profit). (From Random House Unabridged Dictionary, 2d ed, p411, p2005 & p283)
Cholesterol
Cholesterol, LDL
Cholesterol, HDL
Cholesterol Esters
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. (1/41)
BACKGROUND: Small, dense LDL particles are associated with coronary artery disease (CAD) and predict angiographic changes in response to lipid-lowering therapy. Intensive lipid-lowering therapy in the Familial Atherosclerosis Treatment Study (FATS) resulted in significant improvement in CAD. This study examines the relationship among LDL density, hepatic lipase (HL), and CAD progression, identifying a new biological mechanism for the favorable effects of lipid-altering therapy. METHODS AND RESULTS: Eighty-eight of the subjects in FATS with documented coronary disease, apolipoprotein B levels >/=125 mg/dL, and family history of CAD were selected for this study. They were randomly assigned to receive lovastatin (40 mg/d) and colestipol (30 g/d), niacin (4 g/d) and colestipol, or conventional therapy with placebo alone or with colestipol in those with elevated LDL cholesterol levels. Plasma hepatic lipase (HL), lipoprotein lipase, and LDL density were measured when subjects were and were not receiving lipid-lowering therapy. LDL buoyancy increased with lovastatin-colestipol therapy (7.7%; P<0.01) and niacin-colestipol therapy (10.3%; P<0.01), whereas HL decreased in both groups (-14% [P<0.01] and -17% [P<0.01] with lovastatin-colestipol and niacin-colestipol, respectively). Changes in LDL buoyancy and HL activity were associated with changes in disease severity (P<0.001). In a multivariate analysis, an increase in LDL buoyancy was most strongly associated with CAD regression, accounting for 37% of the variance of change in coronary stenosis (P<0.01), followed by reduction in apolipoprotein Bl (5% of variance; P<0.05). CONCLUSIONS: These studies support the hypothesis that therapy-associated changes in HL alter LDL density, which favorably influences CAD progression. This is a new and potentially clinically relevant mechanism linking lipid-altering therapy to CAD improvement. (+info)Role of bile acids and bile acid binding agents in patients with collagenous colitis. (2/41)
BACKGROUND: In a retrospective study bile acid malabsorption was observed in patients with collagenous colitis. AIMS: To study the occurrence of bile acid malabsorption and the effect of bile acid binders prospectively in patients with chronic diarrhoea and collagenous colitis. METHODS: Over 36 months all patients referred because of chronic diarrhoea completed a diagnostic programme, including gastroscopy with duodenal biopsy, colonoscopy with biopsies, and the (75)Se-homocholic acid taurine ((75)SeHCAT) test for bile acid malabsorption. Treatment with a bile acid binder (cholestyramine in 24, colestipol in three) was given, irrespective of the results of the (75)SeHCAT test. RESULTS: Collagenous colitis was found in 28 patients (six men, 22 women), 27 of whom had persistent symptoms and completed the programme. Four patients had had a previous cholecystectomy or a distal gastric resection. The (75)SeHCAT test was abnormal in 12/27 (44%) of the collagenous colitis patients with (75)SeHCAT values 0.5-9.7%, and normal in 15 patients (56%). Bile acid binding treatment was followed by a rapid, marked, or complete improvement in 21/27 (78%) of the collagenous colitis patients. Rapid improvement occurred in 11/12 (92%) of the patients with bile acid malabsorption compared with 10/15 (67%) of the patients with normal (75)SeHCAT tests. CONCLUSION: Bile acid malabsorption is common in patients with collagenous colitis and is probably an important pathophysiological factor. Because of a high response rate without serious side effects, bile acid binding treatment should be considered for collagenous colitis, particularly patients with bile acid malabsorption. (+info)Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. (3/41)
BACKGROUND: The common -514 C-->T polymorphism in the promoter region of the hepatic lipase (HL) gene affects HL activity. The C allele is associated with higher HL activity, more dense and atherogenic LDL, and lower HDL(2) cholesterol. Intensive lipid-lowering therapy lowers HL activity, increases LDL and HDL buoyancy, and promotes coronary artery disease (CAD) regression. We tested the hypothesis that subjects with the CC genotype and a more atherogenic lipid profile experience the greatest CAD regression from these favorable effects. METHODS AND RESULTS: Forty-nine middle-aged men with dyslipidemia and established CAD who were undergoing intensive lipid-lowering therapy were studied. Change in coronary stenosis was assessed by quantitative angiography, HL polymorphism by polymerase chain reaction amplification, HL activity by (14)C-labeled substrate, and LDL buoyancy by density-gradient ultracentrifugation. The response to lipid-lowering therapy was significantly different among subjects with different HL promoter genotypes. Subjects with the C:C genotype had the greatest decrease in HL activity (P<0.005 versus TC and TT by ANOVA) and the greatest improvement in LDL density (P<0.005) and HDL(2)-C (P<0.05) with therapy. These subjects had the greatest angiographic improvement, with 96% of them experiencing CAD regression, compared with 60% of TC and none of the TT patients (P:<0.001). CONCLUSIONS: -In middle-aged men with established CAD and dyslipidemia, the HL gene -514 C-->T polymorphism significantly predicts changes in coronary stenosis with lipid-lowering treatment that appear to involve an HL-associated effect on LDL metabolism. This study identifies a gene polymorphism that strongly influences the lipid and clinical response to lipid-lowering drugs. (+info)Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. (4/41)
Interindividual variability in low density lipoprotein (LDL) cholesterol (LDL-C) response during treatment with statins is well documented but poorly understood. To investigate potential metabolic and genetic determinants of statin responsiveness, 19 patients with refractory heterozygous familial hypercholesterolemia were sequentially treated with placebo, atorvastatin (10 mg/d), bile acid sequestrant, and the 2 combined, each for 4 weeks. Levels of LDL-C, mevalonic acid (MVA), 7-alpha-OH-4-cholesten-3-one, and leukocyte LDL receptor and hydroxymethylglutaryl coenzyme A reductase mRNA were determined after each treatment period. Atorvastatin (10 mg/d) reduced LDL-C by an overall mean of 32.5%. Above-average responders (LDL-C -39.5%) had higher basal MVA levels (34.4+/-6.1 micromol/L) than did below-average responders (LDL-C -23.6%, P<0.02; basal MVA 26.3+/-6.1 micromol/L, P<0.01). Fewer good responders compared with the poor responders had an apolipoprotein E4 allele (3 of 11 versus 6 of 8, respectively; P<0.05). There were no baseline differences between them in 7-alpha-OH-4-cholesten-3-one, hydroxymethylglutaryl coenzyme A reductase mRNA, or LDL receptor mRNA, but the latter increased in the good responders on combination therapy (P<0.05). Severe mutations were not more common in poor than in good responders. We conclude that poor responders to statins have a low basal rate of cholesterol synthesis that may be secondary to a genetically determined increase in cholesterol absorption, possibly mediated by apolipoprotein E4. If so, statin responsiveness could be enhanced by reducing dietary cholesterol intake or inhibiting absorption. (+info)Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. (5/41)
OBJECTIVE: Growth hormone (GH) induces hepatic low-density lipoprotein (LDL) receptors and lowers plasma cholesterol. We characterized the influence of GH treatment on plasma LDL clearance in normal humans and investigated the relative role of LDL receptor (LDLR) activity and stimulation of bile acid synthesis in subjects with different LDLR expression. METHODS AND RESULTS: Plasma clearance of autologous 125I-LDL was measured before and during 3 weeks of treatment with GH (0.1 IU/kg per day) in 9 healthy young males. Plasma LDL cholesterol was reduced by 13% and the fractional catabolic rate of LDL increased by 27%. More marked changes were seen in a patient with hypopituitarism substituted with GH (0.07 IU/kg per day) for 3 months. In a second study, GH dose-dependently reduced LDL cholesterol and increased Lp(a) levels in 3 groups of males: younger and elderly healthy subjects and heterozygous familial hypercholesterolemia (FH). No effect on bile acid synthesis measured by the plasma marker 7alpha-hydroxy-4-cholesten-3-one was observed. In an LDLR-deficient FH homozygote, LDL cholesterol was not affected by GH. CONCLUSIONS: GH treatment reduces plasma LDL cholesterol by inducing LDL clearance. In humans, LDLR expression is a prerequisite for this effect, whereas it is not related to stimulation of bile acid synthesis. (+info)Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo. (6/41)
A sensitive solution hybridization assay using autologous cRNA probes was developed with the aim to study the simultaneous regulation of hepatic mRNA levels, on a quantitative basis, for the LDL receptor (LDLr), HMG-CoA reductase, and cholesterol 7 alpha-hydroxylase (Cho-7-hx) in C57BL/6J mice. With the purpose to suppress and stimulate transcript levels respectively, animals received established high fat diets, cholesterol-enriched diets, and a diet supplemented with mevinolin and colestipol. One hundred nineteen animals were investigated in six separate experiments. In spite of an eightfold increase in hepatic cholesterol induced by a high fat diet, the LDLr and the HMG-CoA reductase mRNA levels were only reduced to 60-70% and 25-50% of control values, respectively. When the data from all animals were analyzed, a strong positive correlation was obtained between the mRNA levels for the LDLr and HMG-CoA reductase (r = 0.79, P less than 0.001). A significant relation remained when control animals only were analyzed (n = 42, r = 0.59, P less than 0.001). Cho-7-hx mRNA showed a regulatory pattern that differed from that of the LDLr and HMG-CoA reductase; feeding cholesterol at 1.7% and 5% but not at 0.4% elevated the mRNA levels for Cho-7-hx while the LDLr and HMG-CoA reductase mRNA levels were maximally suppressed already at 0.4% of dietary cholesterol. The results show that the mRNA levels for the LDLr and HMG-CoA reductase are regulated in parallel in the liver in vivo during various metabolic perturbations as well as at normal physiologic conditions.(ABSTRACT TRUNCATED AT 250 WORDS) (+info)Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. (7/41)
The Cholesterol Lowering Atherosclerosis Study, a randomized angiographic clinical trial, demonstrated the beneficial effect of niacin/colestipol plus diet therapy on coronary atherosclerosis. Outcome was determined by panel-based estimates (viewed in both still and cine modes) of percent stenosis severity and change in native artery and bypass graft lesions. Computer-based quantitative coronary angiography (QCA) was also used to measure lesion and bypass graft stenosis severity and change in individual frames closely matched in orientation, opacification, and cardiac phase. Both methods jointly evaluated 350 nonoccluded lesions. The correlation between QCA and panel estimates of lesion size was 0.70 (p less than 0.0001) and for change in lesion size was 0.28 (p = 0.002). Agreement between the two methods in classifying lesion changes (i.e., regression, unchanged, or progression) occurred for 60% (210 of 350) of the lesions kappa +/- SEM = 0.20 +/- 0.05, p less than 0.001). The panel identified 442 nonoccluded lesions for which QCA stenosis measurements could not be obtained. Lesions not measurable by QCA included those with stenosis greater than 85% that could not be reliably edge tracked, segments with diffuse or ecstatic disease that had no reliable reference diameter, and segments for which matched frames could not be located. Seventy-nine lesions, the majority between 21% and 40% stenosis, were identified and measured by QCA but were not identified by the panel. This comparison study demonstrates the need to consider available angiographic measurement methods in relation to the goals of their use. (+info)Liver X receptor alpha interferes with SREBP1c-mediated Abcd2 expression. Novel cross-talk in gene regulation. (8/41)
The peroxisomal ATP binding cassette (ABC) transporter adrenoleukodystrophy-related protein, encoded by ABCD2, displays functional redundancy with the X-linked adrenoleukodystrophy-associated protein, making ABCD2 up-regulation of therapeutic value. Cholesterol lowering activates human ABCD2 in cultured cells. To investigate in vivo regulation by sterols, we first characterized a sterol regulatory element (SRE) in the murine Abcd2 promoter that is directly bound by SRE-binding proteins (SREBPs). Intriguingly, this element overlaps with a direct repeat 4, which serves as binding site for liver X receptor (LXR)/retinoid X receptor heterodimers, suggesting novel cross-talk between SREBP and LXR/retinoid X receptor in gene regulation. Using fasting-refeeding and cholesterol loading, SREBP accessibility to the SRE/direct repeat 4 was tested. Results suggest that adipose Abcd2 is induced by SREBP1c, whereas hepatic Abcd2 expression is down-regulated by concurrent activation of LXRalpha and SREBP1c. In cell culture, SREBP1c-mediated Abcd2 induction is counteracted by ligand-activated LXRalpha. Finally, hepatic Abcd2 expression in LXRalpha,beta-deficient mice is inducible to levels vastly exceeding wild type. Together, we identify LXRalpha as negative modulator of Abcd2, acting through a novel regulatory mechanism involving overlapping SREBP and LXRalpha binding sites. (+info)
COLESTID® TABLETS (micronized colestipol HCl tablets) Warnings and Precautions | Pfizer Medical Information - Nigeria
Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia. Effects on kinetics...
1990 - Niacin and lovastatin were more efficient than gemfibrozil, probucol, colestipol,
or cholestyramine for...
JoVE Search Results: Colestipol
COLESTID® GRANULES (colestipol HCl for oral suspension) Adverse Reactions | Pfizer Información Médica - Costa Rica
COLESTID® TABLETS (micronized colestipol HCl tablets) Adverse Reactions | Pfizer Medical Information - Nigeria
Drugs - colestipol - usage, dosage, interactions, images - AARP
Evaluation of human panelists in assessing coronary atherosclerosis. | Arteriosclerosis, Thrombosis, and Vascular Biology
Familial hypercholesterolemia - Wikipedia
Alzforum:
AlzRisk Paper Detail
Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis ...
Vermox costo in farmacia, Vermox nezadouci ucinky
Eagle Pills: Can you take viagra with high blood pressure meds original pills!
PatientsLikeMe | Colestipol report for patients like you
Colestipol | YourCareEverywhere
Canadian-Pharmacy
Indomethacin 25 mg sale uk on-line using paypal
Active Constituent
Health Care
Anna Margaret Something About THE Sunshine Starstruck New Music Video | OCEANUP TEEN GOSSIP
Intensive Lipid-Lowering Therapy for Patients With Acute Coronary Syndrome - No Study Results Posted - ClinicalTrials.gov
Plasma Squalene as an Index of Cholesterol Synthesis | Clinical Science | Portland Press
Niacor Information - Drugs and Treatments - MedHelp
Sunlight and Vitamin D improve mood | DrDobbin Nutrition
accureticQuinapril/hctz Oral
Cheap | Empreenda | Page 4
Buy aleve online - Ochotnicza Straż Pożarna Krajowy System Ratowczno-Gaśniczy w Toporzysku
minocycline
buy-minocin-cheap-online
Differences in Sequestrants
Bile acid sequestrant - Wikipedia
Bile Acid Sequestrants and the Treatment of Type 2 Diabetes Mellitus | SpringerLink
Bile Acid Sequestrant Drugs | Grand Strand Health
Which medications in the drug class Bile Acid Sequestrants are used in the treatment of Crohn Disease?
Simvastatin 40 preisvergleich / Clobetasol salbe nrf
METOLAZONE Patient Assistance Program
GIDEON What is new!
Reduction of Serum Cholesterol Levels Alters Lesional Composition of Atherosclerotic Plaques | Arteriosclerosis, Thrombosis,...
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of...
One-Alpha Drops | Medicines.ie
Vytorin Alternatives
DMOZ - Health: Pharmacy: Drugs and Medications: Lipid-Lowering Agents
L-Methylfolate Drug Interactions
Diagnostic scoring for familial hypercholesterolaemia in practice -ORCA
Lojuxta (lomitapide): a novel treatment for homozygous familial hypercholesterolaemia
Familial hypercholesterolaemia - Endodiabesity
Familial hypercholesterolaemia: identification and management - DRO
Familial hypercholesterolaemia | Sonic Genetics
Bile acid sequestrants for cholesterol
Familial hypercholesterolaemia<...
South African Dyslipidaemia Guideline Consensus Statement
Familial hypercholesterolaemia: identification and management | Guidance and guidelines | NICE
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population - Danish National Research Database...
Molecular analysis of patients with familial hypercholesterolaemia (FH): evaluation of two high-throughput mutation analysis...
Colestipol
Drugs.com: Colestipol Hydrochloride "colestipol (Colestid)". MedicineNet. Mutschler E, Schäfer-Korting M (2001). ... ISBN 3-8047-1763-2. Clinical Pharmacology: Colestipol structure Beth Israel Deaconess Medical Center & Care Group: Colestipol ... Colestipol is contraindicated in hypertriglyceridemia (high level of triglycerides in the blood).[citation needed] Colestipol ... Like cholestyramine, colestipol works in the gut by trapping bile acids and preventing them from being reabsorbed. This leads ...
Bile acid sequestrant
Cholestyramine, colestipol and colesevelam have all been used. Doses may not need to be as high as those previously used for ... Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS (March 1980). "Colestipol: a review of its pharmacological properties and ... Colestipol (Colestid, Colestipid) Colesevelam (Cholestagel in Europe, Welchol in the US, Lodalis in Canada) Wilcox C, Turner J ...
Ion-exchange resin
Colestipol is a weakly basic ion-exchange resin and is used to treat hypercholesterolemia. Cholestyramine is a strongly basic ... Colestipol and cholestyramine are known as bile acid sequestrants. Ion-exchange resins are also used as excipients in ... Three ion-exchange resins, sodium polystyrene sulfonate, colestipol, and cholestyramine, are used as active ingredients. Sodium ...
Bile acid malabsorption
Cholestyramine and colestipol, both in powder form, have been used for many years. Unfortunately, many patients find them ...
Poison Prevention Packaging Act of 1970
Colestipol in powder form in packages containing no more than 5 grams of the drug. Conjugated estrogen tablets when dispensed ...
Primary biliary cholangitis
First-line treatment of pruritus consists of anion-exchange resins, such as cholestyramine, colestipol, or colesevalam. These ...
Levothyroxine
... colestipol, and polystyrene sulfonate. Sevelamer with calcium carbonate may decrease the bioavailability of levothyroxine. ...
Sitosterolemia
If dietary treatment alone is insufficient, bile acid-binding resins (e.g., cholestyramine, colestipol) could be considered. In ...
Dyslipidemia
Resins include cholestyramine, colestipol, and colesevalem, and they all decrease LDL-C while increasing HDL-C levels slightly ...
Hyperlipidemia
Bile acid binding resins, such as colestipol, cholestyramine, and colesevelam, function by binding bile acids, increasing their ...
Postcholecystectomy syndrome
... colestipol or colesevelam, which may be better tolerated. Symptoms of postcholecystectomy syndrome may include: Dyspepsia, ...
Hashimoto's thyroiditis
Finally, cholestryamine, colestipol, aluminium hydroxide, ferrous sulphate, and sucralfate are all drugs that decrease T4 ...
Fenofibrate
... colestipol, etc.): If taken together, bile acid resins may bind to fenofibrate, resulting in a decrease in fenofibrate ...
Familial hypercholesterolemia
... cholestyramine or colestipol), nicotinic acid preparations or fibrates. Control of other risk factors for cardiovascular ...
List of MeSH codes (D25)
... colestipol MeSH D25.720.259 - cyanoacrylates MeSH D25.720.259.341 - enbucrilate MeSH D25.720.259.341.110 - bucrylate MeSH ...
List of drugs: Cm-Co
... colestipol (INN) colestolone (INN) colestyramine (INN) colextran (INN) colfenamate (INN) colforsin (INN) colfosceril palmitate ...
List of MeSH codes (D02)
... colestipol MeSH D02.092.782.258 - diamines MeSH D02.092.782.258.174 - cadaverine MeSH D02.092.782.258.368 - ethylenediamines ...
ATC code C10
C10AB08 Ciprofibrate C10AB09 Etofibrate C10AB10 Clofibride C10AB11 Choline fenofibrate C10AC01 Colestyramine C10AC02 Colestipol ...
Colestipol: MedlinePlus Drug Information
Colestipol: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking colestipol,. *tell your doctor and pharmacist if you are allergic to colestipol, any other medications, or any of ... Continue to take colestipol even if you feel well. Do not stop taking colestipol without talking to your doctor. ... Take colestipol exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. ...
Colestipol - Health Library
Before taking colestipol, *tell your doctor and pharmacist if you are allergic to colestipol, any other medications, or any of ... Continue to take colestipol even if you feel well. Do not stop taking colestipol without talking to your doctor. ... Take colestipol exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. ... Colestipol comes as tablets and granules to take by mouth. The tablets are usually taken once or twice daily. The granules are ...
colestipol hydrochloride | Taber's Medical Dictionary
colestipol hydrochloride answers are found in the Tabers Medical Dictionary powered by Unbound Medicine. Available for iPhone ... colestipol hydrochloride is a topic covered in the Tabers Medical Dictionary. To view the entire topic, please log in or ... "Colestipol Hydrochloride." Tabers Medical Dictionary, 24th ed., F.A. Davis Company, 2021. Tabers Online, www.tabers.com/ ... tabersonline/view/Tabers-Dictionary/734682/all/colestipol_hydrochloride. Colestipol hydrochloride. In: Venes DD, ed. Tabers ...
Clinical trial: A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
... and Colestipol as Adjunct Therapy in Lipid Reduction ... or colestipol - Consumes more than 8oz. grapefruit juice daily ... Intervention: Niacin (Drug); Colestipol (Drug); Ezetimibe (Drug). Phase: Phase 4. Status: Completed. Sponsored by: Tuscaloosa ... ezetimibe, niacin, or colestipol Locations and Contacts. Tuscaloosa Research & Education Advancement Corporation, Tuscaloosa, ... A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction. Information ...
Buy Colestid (colestipol hcl) Online | Blink Health
Colestipol is used along with a proper diet to lower cholesterol in the blood. ... Before taking colestipol, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This ... Colestipol is used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for ... Colestipol is used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for ...
Crohn Disease Medication: 5-Aminosalicylic Acid Derivatives, Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Alpha...
Colestipol forms a soluble complex after binding to bile acid, increasing fecal loss of bile acid-bound low-density lipoprotein ... These patients may benefit from bile acid sequestrants such as cholestyramine (2-4 g) and colestipol (5 g 2 or 3 times daily ... These patients may benefit from bile acid sequestrants such as cholestyramine and colestipol. ...
Colestid (Colestipol Hydrochloride)
h1,COLESTID (COLESTIPOL),/h1, ,h2,Colestid Description,/h2, ,p,While cholesterol has many functions in your body, including ... COLESTID (COLESTIPOL). Colestid Description. While cholesterol has many functions in your body, including helping produce bile ... The active ingredient of Colestid is Colestipol, which is classed as a bile acid sequestrant drug. ...
Colestipol (Colestid) | Davis's Drug Guide
Find information on Colestipol (Colestid) in Daviss Drug Guide including dosage, side effects, interactions, nursing ... "Colestipol." Daviss Drug Guide, 18th ed., F.A. Davis Company, 2023. Daviss Drug Guide - OLD - USE 2.0, www.drugguide.com/ddo/ ... view/Davis-Drug-Guide/51172/all/colestipol. Vallerand AHA, Sanoski CAC, Quiring CC. Colestipol. Daviss Drug Guide. F.A. Davis ... colestipol is a topic covered in the Daviss Drug Guide. To view the entire topic, please log in or purchase a subscription. ...
Generic Colestid Availability - Drugs.com
colestipol hydrochloride granule;oral. * Manufacturer: IMPAX LABS. Approval date: May 2, 2006. Strength(s): 5GM/SCOOPFUL [AB], ... COLESTID (colestipol hydrochloride - tablet;oral). * Manufacturer: PFIZER. Approval date: July 19, 1994. Strength(s): 1GM [RLD] ... colestipol hydrochloride tablet;oral. * Manufacturer: IMPAX LABS. Approval date: October 24, 2006. Strength(s): 1GM [AB] ... COLESTID (colestipol hydrochloride - granule;oral). * Manufacturer: PFIZER. Approval date: September 22, 1995. Strength(s): 5GM ...
Colestipol - For All Medical Treatment Options Explained, Visit CureCrowd
Cholesterol Drugs: What to Expect With Heart Medication
Prescribed for: Colestipol (Colestid) is used for the treatment of high cholesterol in conjunction with dietary control; for ... colestipol (Colestid). Drug Class: Bile acid sequestrants. Prescription: Yes. Generic: Yes. Preparations: Tablet of 1 gm. ... Side effects: Side effects of colestipol (Colestid) include constipation, stomach upset, heartburn, indigestion, belching, gas ...
ATSDR - Oak Ridge Reservation - ORRHES Meeting Minutes
DailyMed - CLINDAMYCIN PHOSPHATE lotion
Crohn Disease: Practice Essentials, Background, Pathophysiology
Mycophenolate Mofetil (Oral Route) Before Using - Mayo Clinic
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.. ...
DailyMed - LEVOTHYROXINE SODIUM tablet
Listing of Drugs Currently Regulated as New Drugs (The New Drugs List) - Canada.ca
RxAssist - RXOUTREACH Patient Assist Program
Pro-Indapamide - Uses, Side Effects, Interactions - MedBroadcast.com
Triquilar - Uses, Side Effects, Interactions - MedBroadcast.com
Our Pfizer Products Hold the Cure | Pfizer
In this section find an overview of our Pfizer Products and search for information on our most popular Pfizer products. Our products are the results of 1500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription. Our Pfizer products hold the cure.
How Cholesterol Works | HowStuffWorks
Dynacin, Minocin (minocycline) dosing, indications, interactions, adverse effects, and more
Psyllium Information | Mount Sinai - New York
All About Cholesterol-Lowering Medicines - AHealthyMe - Blue Cross Blue Shield of Massachusetts
Human Metabolome Database
Nuzyra (omadacycline) dosing, indications, interactions, adverse effects, and more
Primary biliary cirrhosis: MedlinePlus Medical Encyclopedia
ColestidCholestyramine or colestipolColesevelamHydrochlorideResinsSequestrantsAntacidsMedicationsEzetimibeColestyramineDecreaseCholesterolBile saltsHttpsEffectsTherapyColesevelamEffect of colestipol hydrochlorideFast does decadronActive ingredientAbsorptionBindsHydrochloride tabletsDrugsGranulesClofibrateBiliaryDoseMedicationDescriptorSerumResinDietaryInsolubleGemfibrozilLiverExposureLevelsMinorHighPatientsResultsAgentsSide effects
Colestid2
- The active ingredient of Colestid is Colestipol, which is classed as a bile acid sequestrant drug. (discountdrugsfromcanada.com)
- Colestipol is the generic alternative to Colestid. (onlinepharmaciescanada.com)
Cholestyramine or colestipol6
- Cholestyramine (or colestipol) may reduce the itching. (medlineplus.gov)
- A healthcare professional may prescribe medications for those experiencing moderate to severe pruritis, such as cholestyramine or colestipol. (medicalnewstoday.com)
- Take cholestyramine or colestipol an hour before or four hours after taking hydrochlorothiazide if you also take either of those medications. (prescriptiongiant.com)
- Separate dosing by ≥4hrs before or 4-6hrs after cholestyramine or colestipol resins. (empr.com)
- If you are taking cholestyramine or colestipol, take it 4 to 6 hours before or 1 hours after gemfibrozil. (singhealth.com.sg)
- If you also take certain drugs to lower your cholesterol (bile acid-binding resins such as cholestyramine or colestipol), take irbesartan/hydrochlorothiazide at least 4 hours before or at least 4 to 6 hours after these medications. (healthwarehouse.com)
Colesevelam1
- These include cholestyramine, colesevelam, and colestipol. (ahealthyme.com)
Hydrochloride2
- colestipol hydrochloride is a topic covered in the Taber's Medical Dictionary . (tabers.com)
- Taber's Online , www.tabers.com/tabersonline/view/Tabers-Dictionary/734682/all/colestipol_hydrochloride. (tabers.com)
Resins1
- Antagonized by cholestyramine, colestipol resins. (hematologyadvisor.com)
Sequestrants2
- Colestipol is in a class of medications called bile acid sequestrants. (medlineplus.gov)
- These patients may benefit from bile acid sequestrants such as cholestyramine (2-4 g) and colestipol (5 g 2 or 3 times daily before meals). (medscape.com)
Antacids1
- This includes aluminium-containing antacids, colestipol, phenobarbital and the combined oral contraceptive pill. (who.int)
Medications7
- Unless otherwise instructed, take all other medications at least 1 hour before or 4 hours after you take colestipol because it can interfere with their absorption. (medlineplus.gov)
- tell your doctor and pharmacist if you are allergic to colestipol, any other medications, or any of the ingredients in colestipol preparations. (medlineplus.gov)
- Patients are titrated as tolerated to therapeutic doses of study medications (ezetimibe 10mg/day, niacin 1500mg/day, and colestipol 20gm/day). (druglib.com)
- Colestipol may decrease your absorption of other medications. (blinkhealth.com)
- Take your other medications as directed by your doctor, usually at least 1 hour before or 4 to 6 hours after colestipol. (blinkhealth.com)
- Colestipol, a drug for lowering cholesterol, is another one that fights against blood pressure medications. (dummies.com)
- MedlinePlus lists cholestyramine, colestipol, medications containing the hormone estrogen, protease inhibitors, retinoids, certain anti-psychotics and birth control pills as medications that can cause false high triglyceride readings. (livestrong.com)
Ezetimibe2
- To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or niacin. (druglib.com)
- Patients are randomized into one of three groups to receive ezetimibe, niacin, or colestipol in addition to current statin therapy. (druglib.com)
Colestyramine1
- Reduced bioavailability w/ colestyramine or colestipol. (mims.com)
Decrease1
- Colestipol is used along with diet changes to decrease the amount of fatty substances such as low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in certain people with high cholesterol. (medlineplus.gov)
Cholesterol1
- Colestipol is used along with a proper diet to lower cholesterol in the blood. (blinkhealth.com)
Bile salts1
- Cholestyramine and colestipol are effective in sequestering bile salts in the enteric lumen. (medscape.com)
Https1
- 2023. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51172/all/colestipol. (drugguide.com)
Effects2
- Colestipol may cause side effects. (medlineplus.gov)
- Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. (semanticscholar.org)
Therapy1
- Stein EA, Heimann KW: Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia. (hmdb.ca)
Colesevelam3
- Bile-acid binding agents such as cholestyramine, colestipol , and colesevelam have been investigated for IBS-D. (nih.gov)
- IF YOU ARE ALSO TAKING A BILE ACID SEQUESTRANT (such as cholestyramine, colestipol, or colesevelam), take this medicine at least 2 hours before or at least 4 hours after the bile acid sequestrant. (canadapharmacy.com)
- Colesevelam binds to bile acids with higher affinity than colestyramine or colestipol, how fast does decadron injection work. (thesalarmy.com)
Effect of colestipol hydrochloride2
- Although the significance of this finding has not been established in clinical studies, the elevation of the lipoprotein LpAI particle within the HDL fraction is consistent with an antiatherogenic effect of colestipol hydrochloride, even though little change is observed in HDL cholesterol (HDL-C). (nih.gov)
- Modification of the carcinogenic process in colorectal cancer by endogenous and exogenous factors: effect of colestipol hydrochloride on tumors induced by dimethylhydrazine. (nih.gov)
Fast does decadron1
- Not HGH, anabolic colestipol, how fast does decadron using steroids without a prescription can cause unpleasant side effects that go beyond drug charges and being labelled a cheater. (towermadness.com)
Active ingredient1
- The active ingredient in colestipol hydrochloride tablets is micronized colestipol hydrochloride, which is a lipid lowering agent for oral use. (nih.gov)
Absorption4
- colestipol will decrease the level or effect of mycophenolate by inhibition of GI absorption. (medscape.com)
- colestipol decreases levels of digoxin by inhibition of GI absorption. (medscape.com)
- It is also best taken at least four hours apart from calcium, iron, cholesterol-lowering drugs (cholestyramine, colestipol), and multivitamin tablets that contain iron, as these can decrease absorption. (btf-thyroid.org)
- Cholestyramine, Colestipol, Neomycin cause decreased absorption of β carotene. (com.bd)
Binds2
- Colestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces. (nih.gov)
- Colestipol binds to the bile acids in the intestine and prevents them being reabsorbed into the bloodstream. (dxline.info)
Hydrochloride tablets3
- Colestipol hydrochloride tablets are light yellow in color and are tasteless and odorless. (nih.gov)
- Colestipol hydrochloride tablets contain no calories. (nih.gov)
- For example, Impax couldn't demonstrate that the manufacturing process for fenofibrate capsules was capable of controlling weight variations and didn't have data to support the temperature range used during the granulation process of colestipol hydrochloride tablets, according to the warning letter. (fdanews.com)
Drugs1
- Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list.html. (healthbloom.ca)
Granules3
- Colestipol comes as tablets and granules to take by mouth. (medlineplus.gov)
- A 65-year-old man with type IIa dyslipidemia who received flavored colestipol granules 2 scoops/day for 3 months developed asymptomatic hepatotoxicity. (nih.gov)
- Colestipol granules in the colon: macroscopic and microscopic findings. (nih.gov)
Clofibrate1
- Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia. (nih.gov)
Biliary1
- Colestipol is a nonabsorbed bile acid sequestrant that is used a therapy of hyperlipidemia and for the pruritus of chronic liver disease and biliary obstruction. (nih.gov)
Dose3
- In humans, less than 0.17% of a single 14 C-labeled colestipol hydrochloride dose is excreted in the urine when given following 60 days of dosing of 20 grams of colestipol hydrochloride per day. (nih.gov)
- Low dose colestipol in adolescents with familial hypercholesterolaemia. (nih.gov)
- OLYAEI, DEMATTOS BENNETT Atorvastatin Cholestyramine Colestipol Fluvastatin Gemfibrozil Lovastatin Pravastatin Simvastatin Starting dose forex powerpoint mgday 4 g bid 5 gbid 20 mg daily 600 poewrpoint 5 mg daily 10-40 mg daily 5-20 mg daily Maximum dose 80 mgday 24 gday 30 gday 80 mgday 600 bid 20 mgday 80 mgday 20 mgday Table 5. (binaryoptionsxpert.com)
Medication1
- Colestipol, a cholesterol-lowering medication similar to cholestyramin, may also reduce beta-carotene levels. (stlukes-stl.com)
Descriptor1
- Colestipol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (ouhsc.edu)
Serum5
- Although colestipol hydrochloride produces an increase in the hepatic synthesis of cholesterol in man, serum cholesterol levels fall. (nih.gov)
- Serum triglyceride levels may increase or remain unchanged in colestipol hydrochloride treated patients. (nih.gov)
- The decline in serum cholesterol levels with colestipol hydrochloride treatment is usually evident by one month. (nih.gov)
- When colestipol hydrochloride is discontinued, serum cholesterol levels usually return to baseline levels within one month. (nih.gov)
- One week after discontinuing colestipol, serum transaminases fell dramatically, with some returning to normal limits. (nih.gov)
Resin2
Dietary2
- When carcinogen-treated animals received dietary colestipol (0.52%, w/w) from 4 weeks prior to the first injection of dimethylhydrazine until the time of death, there was an increase in the number of tumors per tumor-bearing animal to 2.23. (nih.gov)
- In an attempt to understand the nature of this enhancement, animals were administered dietary colestipol at different times in relation to the administration of the carcinogen. (nih.gov)
Insoluble2
- Colestipol is an insoluble, high molecular weight basic anion-exchange copolymer of diethylenetriamine and 1-chloro-2, 3-epoxypropane, with approximately 1 out of 5 amine nitrogens protonated (chloride form). (nih.gov)
- Colestipol hydrochloride is hydrophilic, but it is virtually water insoluble (99.75%) and it is not hydrolyzed by digestive enzymes. (nih.gov)
Gemfibrozil1
- if you are taking gemfibrozil (Lopid), take it 2 hours before or 2 hours after colestipol. (medlineplus.gov)
Liver2
Exposure1
- pre-initiation colestipol exposure, 2.23. (nih.gov)
Levels1
- colestipol decreases levels of lomitapide by drug binding in GI tract. (medscape.com)
Minor1
- This graph shows the total number of publications written about "Colestipol" by people in this website by year, and whether "Colestipol" was a major or minor topic of these publications. (ouhsc.edu)
High3
- The high molecular weight polymer in colestipol hydrochloride apparently is not absorbed. (nih.gov)
- A high response rate to open label treatment with colestipol supports this, but placebo-controlled studies are warranted. (bmj.com)
- The bile acid sequestrants (cholestyramine, colestipol) and nicotinic acid have been the mainstays of pharmacologic therapy for patients with phenotype(s) IIA and IIB hyperlipoproteinemia, but produce symptomatic side effects in a high percentage of patients. (ccjm.org)
Patients1
- Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. (nih.gov)
Results1
- Treatment with colestipol results in a significant increase in lipoprotein LpAI. (nih.gov)
Agents1
- Since colestipol has the capacity to bind a number of chemical agents, the different biological effects probably reflect the multifactorial nature of colorectal cancer with the end result dependent on the balance between opposing factors. (nih.gov)
Side effects1
- Colestipol may cause side effects. (medlineplus.gov)